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ABSTRACT 
Chronic heart failure (CHF) is a global public health problem. Despite all 
the technical advances available in modern cardiology, a medical strategy 
for the treatment of CHF has been and remains the main focus of 
therapeutic intervention. А particular problem is the treatment of CHF with 
concomitant pathology. The modern pharmacological strategy for the 
treatment of patients with CHF and iron deficiency anemia, except iron 
preparations, must take into account the use of agents that have 
antihypoxic, antioxidant and membrane-stabilizing effects, and at the same 
time regulatory effect on the metabolism of physiologically active 
compounds to improve the condition of patients. Therefore, this study is 
aimed to evaluate the effectiveness of iron deficiency anemia’s correction, 
identify and compare the effect of oral ferrotherapy and combined use of 
ferrotherapy with L-carnitine on clinical and instrumental parameters of 
patients with chronic heart failure with reduced ejection fraction of left 
ventricle as possible variants of additional therapy to standard treatment. 
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Introduction. Chronic heart failure (CHF) with reduced left ventricular (LV) ejection fraction 
(EF) is a clinical syndrome of dyspnea, exercise intolerance and/or edema resulting from an 
impairment of ejection of blood, usually documented by a left ventricular ejection fraction of 40% or 
less on echocardiography [1]. In recent years, researchers have focused on the comorbidity of CHF. 
Anemia as a manifest form of ID is a frequent finding in adults with CHF [2]. The incidence of 
anemia appears to grow with increase in functional class (FC) of chronic heart failure according to NYHA 
classification – at FC III to 33% and at FC IV to 80% [3, 4]. An important clinical aspect is that iron 
deficiency anemia (IDА), except sideropenic syndrome, manifests with nonspecific symptoms. Symptoms 
such as dyspnea and fatigue may be difficult to distinguish from symptoms of HF. Therefore, it can be 
diagnosed only by determining the laboratory parameters while the anemia syndrome during CHF is 
associated with an increase in mortality and the frequency of hospitalizations of patients [5, 6, 7].  
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Correction of anemia in CHF is important to improve subjective, functional treatment 
outcomes and to optimize long-term prognosis [8]. According to modern approaches to correction of 
IDA of patients with CHF peroral and parenteral ferrocorrection are the most often used ones. Several 
studies have been conducted to determine which ferrocorrection method is better.  
Аnalysis of intravenous iron effectiveness in patients with HF and ID showed an increase of 
the 6-minute walk test distance and of numerous secondary points related to functional capacity [9]. 
However, it remained unclear whether such improvements could be obtained with a much easier to 
administer, more readily available, and less expensive oral iron formulation.  
The IRONOUT-HF trial investigated whether oral, rather than intravenous, iron supplementation 
could improve peak exercise capacity in patients with CHF with reduced LVEF and ID. Contrary to the 
supportive findings above, no significant change was seen in the point of change in peak oxygen uptake or 
change in 6-minute walk and quality of life. Also, little change was evident in the indices of iron stores over 
the course of the study, with only a 3% increase in transferrin saturation (ТS) and an 11 ng/mL increase in 
ferritin. The intravenous trials resulted in a 4-fold greater increase in ТS and a 20-fold greater increase in 
ferritin [9]. Of note, in all the trials discussed below, iron deficiency was diagnosed in the setting of heart 
failure as ferritin less than 100 ng/mL (absolute iron deficiency) or as ferritin 100 to 300 ng/mL with 
transferrin saturation less than 20% (relative deficiency) [10].  
In our opinion for the effective treatment of patients with CHF and iron deficiency with anemic 
syndrome, it is necessary to differentiate the variant of iron metabolism. IDА is caused by the multifactorial 
depletion of iron in the body and the main way of its correction is the use of oral or intravenous iron. 
Hepcidin function to block intestinal iron absorption and iron release from the mononuclear-phagocyte 
system, which occur due to activation of proinflammatory cytokines, have an impact on the development of 
ACD as a functional ID. Therefore, the use of oral iron supplements in this type of ID is not effective and, 
moreover, dangerous due to possible occurrence of hemosiderosis [11]. 
Futhermore, the modern pharmacological strategy for the treatment of patients with CHF and 
IDA, except iron preparations, must take into account the use of agents that have antihypoxic, 
antioxidant and membrane-stabilizing effects, and at the same time regulatory effect on the 
metabolism of physiologically active compounds to improve the condition of patients. 
The purpose of the study is to evaluate the effectiveness of IDA correction, identify and 
compare the effect of oral ferrotherapy and combined use of ferrotherapy with L-carnitine on clinical 
and instrumental parameters of patients with CHF with reduced LVEF as possible variants additional 
therapy to standard treatment. 
Material and methods. 62 patients with CHF with reduced LVEF due to hypertensive and 
ischemic heart disease, FC II-III according to NYHA were examined. All patients had differentiated 
IDA. There were 72.6 % males and 27.4 % females; and the mean age was 70.0 ± 0.9 years. 
Number of red blood cells (Rbc), hemoglobin (Hb) level, color index (CI), hematocrit (Hct), 
serum iron (SI), ТS, 6-minute walk stress test, MLHFQ questionnaire and LV morpho-functional 
parameters by echocardiography were determined. 
Only patients with absolute ID and anemic syndrome – IDA were included in the study. 
For the diagnosis of IDA, the following criteria were used: 1) laboratory signs of anemia – a 
decrease Hgb level in men <130 g/l and in women <120 g/l; 2) a decrease in SI in women <11.5 
µmol/l and in men <13.0 µmol/l; 3) ferritin level <100 ng/ml. Only patients with mild and moderate 
anemia were included in the study. 
All patients received standard therapy indicated by modern ESC recommendations, taking into 
account ischemic and hypertensive etiology of CHF and comorbid conditions.  
The patients were divided in two groups: in addition to the standard therapy, the patients in the 
1st group (n=32) were prescribed oral ferrous sulfate in a dose of 320 mg, equivalent to 100 mg of 
bivalent iron and 60 mg of ascorbic acid 2 tablets per day for 6 months; the patients in the 2nd group 
(n=30) received the standard therapy of CHF and not only iron, but also L-carnitine. 
The groups of patients were compared by main clinical characteristics. 
Statistical processing of the obtained results was performed using the software package 
Microsoft Office Excel and Statistica. The obtained measurements are presented as a median (lower, 
upper quartile). The statistical significance of the difference in the measured parameters was 
calculated according to Kruskal-Wallis ANOVA & Median test for all groups criterion and to 
Wilcoxon matched pairs test criterion. The difference was considered reliable at p<0.05.  
Research results. Table 1 presents the laboratory and instrumental parameters after treatment of 
patients. It was found that the use of two variants of ferrocorrection as an application to standard CHF 
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treatment among the total number of patients with IDA testified to a sufficient effect both to eliminate signs 
of anemia and to eliminate ID. Comparison of the studied laboratory parameters of patients with different 
options for additional treatment after 6 months revealed no difference in the increase in parameters. 
Also no difference in the dynamics of myocardium morpho-functional indices between two 
groups over 6 months of observation was detected.  
However, patients with ferrotherapy and L-carnitine had the tendency to more positive 
dynamics of ECHO-CG parameters – EDD (end-diastolic dimension) decreased by 6.6% (p<0.0001), 
EDV (end-diastolic volume) by 14.1% (p<0.0001), ESD (end-systolic dimension) by 6% (p<0.0001), 
ESV (end-systolic volume) by 19.4% (p<0.0001) and EF increased by 19.6% (p<0.0001). EDD 
decreased by 5% (p<0.0001), EDV by 11.3% (p<0.0001), ESD by 4,8% (p<0.0001), ESV by 17.1% 
(p<0.0001) and EF increased by 16.4% (p<0.0001) in group of patients with only ferrotherapy. 
Analysis of the dynamics of the covered six-minute walk test distance in patients on the 
background of the standard treatment and additional ferrotherapy over six months demonstrated an 
increase in the actual distance by 8.9% (from 249.5 to 372,3 m, р<0,0001). The change of the covered 
six-minute walk test distance in patients on the background of the standard treatment and additional 
ferrotherapy with L-carnitine was with more positive dynamics. Thus, as compared to the initial indices 
over 6 months, the covered distance increased by +19,4% (from 259 to 304,5 m, р<0,0001). 
At the end of the study, it was also found that among all patients, after 6 months of treatment, 
the level of QOL compared to baseline improved by 14.7% according to the MLHFQ (from 59 to 51 
points, p <0.0001) 
Analysis of the dynamics of QOL in patients with standard treatment and additional ferrotherapy 
over six months demonstrated the negative change in MLHFQ score by 13.7% (from 60.5 to 52 points, p 
<0.0001), indicating positive QOL dynamics while the analysis of changes in the level of QOL in patients 
with IDA which received not only 6-month ferrotherapy but also L-carnitine revealed a greater dynamics of 
the indicator – a negative increase of 16.2% (from 59 to 48.9 points, p <0,0001). 
Table 1. Comparison of laboratory and instrumental parameters of patients with CHF with 
reduced LVEF and IDA after treatment 
Parameters 
6-month ferrotherapy 
n=32 
6-month ferrotherapy 
with L-carnitine 
n=30 
Initial value 6th month 
Dynamics, 
% 
Initial value 6th month 
Dynamics, 
% 
1 2 3 4 5 6 7 
Hematological parameters 
Hb, g/l 
106.5 
(96.5;116.5) 
138 
(131.5; 147)** 
+28.6 
(+25.3;+34.5) 
108 
(97; 116) 
141 
(134; 147)** 
+31.6 
(+24.8;+36.8) 
Rbc, 
×1012/l 
4.25 
(3.9; 4.48) 
4.6 
(435; 4.9)** 
+8.9 % 
(+3.9; +14.6) 
3.9 
(3.87; 4.45) 
4.6 
(4.3; 4.9)** 
+11.5 
(+5.6; +15.6) 
СІ 
0.77 
(0.70; 0.84) 
0.88 
(0.86; 0.94)** 
+17.6  
(+8; +22) 
0.80 
(0.7; .82) 
0.91 
(0.89; 0.95)** 
+15.9 
(+8.3; +22.2) 
Hсt, l/l 
0.32 
(0.32; 0.36) 
0.37 
(0.35; 0.41)** 
+12.5  
(+9.2; +21.5) 
0.32 
(0.31; 0.35) 
0.39 
(0.37; 0.4)** 
+19.6 
(+14.1;+25)# 
SI, umol/l 
7.9 
(6.2; 10,3) 
15.3 
(12.9; 18)** 
+82.6  
(+63,6; an 
increase of 
2.1 times) 
9.55 
(6.4; 11,2) 
16 
(13.7; 18,4)** 
+87.2  
(+62.8; an 
increase of 
2.1 times) 
Ferritin, 
ng/ml 
63 
(41; 82.5) 
133.5 
(99; 179)** 
an increase 
of 2.3 times 
(+90.4; of 
3.2 times) 
43.5 
(31; 76) 
119 
(104; 158)** 
an increase 
of 2.5 times  
(of 2; of 3.2 
times) 
TS, % 
11.1 
(8; 13.3) 
23.7 
(17.7; 30)** 
an increase 
of 2.2 times 
(+77.8; of 
2.8 times) 
12.8 
(8; 15.2) 
27 
(20.4; 32.3)** 
an increase 
of 2.2 times 
(+76.8; of 
2.8 times) 
TIBC, 
umol/l 
77 
(67.5; 87.7) 
65.5 
(59; 74.5)** 
-13.6 
(-17.7; -7.4) 
74.1 
(68.2; 86.5) 
64.1 
(57; 69)** 
-17.8 
(-22.5;-7.47)# 
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Continuation of table 1. 
1 2 3 4 5 6 7 
Echo-CG indices 
EDD, mm 
59  
(55,8; 62,9) 
56,6  
(54; 59) 
-5  
(-7,4; -1,83) 
61 
(59; 65) 
58 
(55; 60) 
-6,6 
(-7,7; -4,0) 
ESD, mm 
49,1 
(46,3; 52,8) 
47 
(44; 49) 
-4,8 
(-7,5; -2,2) 
52 
(49; 54,2) 
48 
(46; 50,2) 
-6,0  
(-8,7; -4,4) 
EDV, ml 
173.2  
(152.7; 197.7) 
157.8  
(140.6; 174.1) 
-11.3 
(-15.6; -2.9) 
186.9  
(173.2; 216) 
163.3 
(147.4; 180) 
-14.1 
(-16.7; -4.9) 
ESV, ml 
113.3  
(101.3; 134.5) 
95.7 
(82; 107.7) 
-17.1 
(-22; -10.6) 
129.5 
(112.8; 142.5) 
101 
(86; 112) 
-19.4 
(-24.9; -14.0) 
LVEF, % 
35.1 
(32.6; 35.8) 
40.4 
 (38.4; 42.7) 
+16.4  
(13.4; 22) 
34.7  
(33.2; 35.7) 
41.9 
(38.7; 45.9) 
+19.6 
(14.5; 24.2) 
Additional parameters 
6-minute 
walk stress 
test, meters 
248,5 
(212.5; 293.5) 
270 
(239; 320) 
+11.8 
(1.2; 17.4) 
259 
 (210; 301) 
304,5 
(258; 360) 
+19,4 
(12.6; 22.7)@ 
QOL, 
points: 
MLHFQ 
60.5 
(54; 66) 
52 
(47; 58.5)** 
-13.7 
(-14.9;-8.7) 
59 
 (54; 63) 
48.5 
(44; 55)** 
-16.2 
(18.5; -13.6)# 
Notes: EDD – end-diastolic dimension, EDV – end-diastolic volume, ESD – end-systolic dimension, 
ESV – end-systolic volume, EF – left ventricular ejection fraction, QOL – quality of life, MLHFQ – 
The Minnesota Living With Heart Failure Questionnaire. 
«*» p <0.01 when compared with initial values; "**" p <0.0001 when compared with initial values; 
"#" p <0.05 when comparing values of different observation groups after treatment;  
"@" p <0.001 when comparing values of different observation groups after treatment. 
Conclusions. 1. It has been detected that iron deficiency anemia’s correction in patients with 
chronic heart failure, who received combination of standart treatment with ferrotherapy is 
accompanied by an increase in the level of hematological parameters.  
2. Favorable changes in erythropoiesis were accompanied by a positive dynamics of the 
morphofunctional parameters of the myocardium, the distance during the 6-minute walk test and the 
quality of life indicators. 
3. The use of L-carnitine with oral ferrotherapy is accompanied by a greater increase in 
exercise tolerance, better hemodynamic effects of therapy and a more significant improvement in 
quality of life among patients compared with using only iron sulfate ferrocorrection. 
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